Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 11/20 | 0.38 |
| ▸ | JAK1 | P23458 | 11/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | DTYMK | P23919 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5747116 | 0.87 | POLB (0.41) | POLBJAK2JAK1GPR119GRM5 | |
| SCHEMBL5748387 | 0.87 | POLB (0.41) | POLBJAK2JAK1GPR119GRM5 | |
| SCHEMBL5748603 | 0.87 | POLB (0.41) | POLBJAK2JAK1GPR119GRM5 | |
| SCHEMBL5775824 | 0.82 | POLB (0.47) | POLBGPR119GRM5DTYMKMAP4K4 | |
| SCHEMBL633008 | 0.77 | USP30 (0.42) | POLBGPR119GRM5DTYMK | |
| SCHEMBL5747118 | 0.76 | OPRK1 (0.38) | GRM5OPRD1OPRK1 | |
| SCHEMBL5509551 | 0.71 | ALDH1A1 (0.42) | POLBGPR119 | |
| SCHEMBL3492076 | 0.71 | JAK2 (0.53) | POLBJAK2JAK1GPR119GRM5 | |
| SCHEMBL5801155 | 0.70 | KCNH2 (0.42) | JAK2JAK1GPR119MAP4K4 | |
| SCHEMBL5739690 | 0.70 | NFKB1 (0.33) | JAK2JAK1GPR119MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1419155-B1 | PIPERIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2006-11-08 | — | — | EP | disclosed |
| US-20040198756-A1 | Medicaments | SMITHKLINE BEECHAM PLC (GB) | 2004-10-07 | — | — | US | disclosed |
| EP-1419155-A2 | PIPERIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2004-05-19 | — | — | EP | disclosed |
| WO-2003010138-A2 | PIPERIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198756-A1 | Medicaments | PIGO, PSAP, CD68 | POLB 980/4885JAK2 1673/4885JAK1 2925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.